登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《PubMed，2月5日，Potential antiviral therapeutics for 2019 Novel Coronavirus》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-02-07

  • Potential antiviral therapeutics for 2019 Novel Coronavirus

    Li H, Wang YM, Xu JY, Cao B.

    doi: 10.3760/cma.j.issn.1001-0939.2020.0002.

    Abstract

    The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains - severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir / ritonavir, lopinavir / ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.

  • 原文来源：https://www.ncbi.nlm.nih.gov/pubmed/32023685
32浏览量
原文链接
相关报告

  • 《JCM，2月26日，Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-01
    • Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review by Junxiong Pang 1,2,*,Min Xian Wang 1,2,Ian Yi Han Ang 1,Sharon Hui Xuan Tan 1,Ruth Frances Lewis 1,Jacinta I-Pei Chen 1,Ramona A Gutierrez 3,Sylvia Xiao Wei Gwee 1,2,Pearleen Ee Yong Chua 1,2,Qian Yang 1,Xian Yi Ng 1,Rowena KS Yap 1,Hao Yi Tan 1,Yik Ying Teo 1,Chorh Chuan Tan 4,Alex R. Cook 1,Jason Chin-Huat Yap 1 andLi Yang Hsu 1 1 Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117549, Singapore 2 Centre for Infectious Disease Epidemiology and Research, National University of Singapore, Singapore 117549, Singapore 3 National Centre for Infectious Diseases, Singapore 308442, Singapore 4 Ministry of Health, Singapore 169854, Singapore * Author to whom correspondence should be addressed. J. Clin. Med. 2020, 9(3), 623; https://doi.org/10.3390/jcm9030623 Received: 13 February 2020 / Revised: 17 February 2020 / Accepted: 19 February 2020 / Published: 26 February 2020 Abstract Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major electronic databases (PubMed, Embase and Cochrane Library) to identify published studies in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Supplementary strategies through Google Search and personal communications were used. A total of 27 studies fulfilled the criteria for review. Several laboratory protocols for confirmation of suspected 2019-nCoV cases using real-time reverse transcription polymerase chain reaction (RT-PCR) have been published.
    194浏览量
    原文链接

  • 《AnnalsofIM，2月5日，Reporting, Epidemic Growth, and Reproduction Numbers for the 2019 Novel Coronavirus (2019-nCoV) Epidemic》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-02-06
    • Reporting, Epidemic Growth, and Reproduction Numbers for the 2019 Novel Coronavirus (2019-nCoV) Epidemic Ashleigh R Tuite , David N Fisman PMID: 32023340 DOI: 10.7326/M20-0358 Background: Virologically confirmed cases of 2019 novel coronavirus (2019-nCoV) in China and other countries have increased sharply (1, 2), leading to concerns regarding its pandemic potential. Viral epidemiology has been characterized sufficiently to permit construction of transmission models that predict the future course of this epidemic (3). Objective: To provide insight into the changing nature of case findings and epidemic growth. Methods: We developed a simple disease-transmission model in which the 2019-nCoV epidemic was modeled as a branching process starting in mid-November 2019, with a serial interval of 7 days (time between cases) and a basic reproduction number (R0) of 2.3 (new cases from each old case), based on available data and assuming no intervention (Figure 1). The epidemic start date aligned our modeled case counts to point estimates from international case exportation data (4). The model estimated plausible values of the effective reproduction number (Re; reproduction number in the presence of control efforts) after implementation of a quarantine in Wuhan and surrounding areas of China on 24 January 2020 (3) (Figure 1).
    37浏览量
    原文链接